Clinical Trials Browser

Phase 2 × INDUSTRY × Oligodendroglioma × Clear all

NCT05267106 2025-12-30

FIGHT-209

Phase 2 Terminated

83 enrolled 18 charts

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Phase 2 Completed

151 enrolled 45 charts 1 FDA

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

NCT01986348 2023-01-26

KING

Phase 2 Terminated

76 enrolled 16 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT00392171 2017-06-07

The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

Phase 2 Completed

120 enrolled 6 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT00389090 2012-02-09

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Phase 2 Terminated

Astrocytoma, Glioma, Oligodendroglioma

NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Phase 2 Terminated

Astrocytoma, Glioblastoma, Oligodendroglioma